Blackhawk Capital Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-17,267
Closed -$458K 149
2024
Q4
$458K Sell
17,267
-9,930
-37% -$269K 0.24% 92
2024
Q3
$787K Sell
27,197
-1,685
-6% -$49.2K 0.42% 73
2024
Q2
$808K Sell
28,882
-3,450
-11% -$95K 0.49% 68
2024
Q1
$897K Buy
+32,332
New +$897K 0.56% 62
2023
Q4
Sell
-16,033
Closed -$532K 98
2023
Q3
$532K Sell
16,033
-22,917
-59% -$810K 0.39% 70
2023
Q2
$1.43M Buy
38,950
+1,962
+5% +$76.4K 0.99% 40
2023
Q1
$1.51M Buy
+36,988
New +$1.6M 1.1% 34
2019
Q3
Sell
-51,089
Closed -$2.1M 98
2019
Q2
$2.1M Buy
51,089
+1,684
+3% +$66.9K 2.01% 13
2019
Q1
$1.99M Buy
49,405
+2,848
+6% +$114K 2.06% 14
2018
Q4
$1.93M Buy
46,557
+560
+1% +$23.2K 2.46% 12
2018
Q3
$1.92M Buy
45,997
+16,073
+54% +$619K 2.72% 10
2018
Q2
$1.03M Buy
29,924
+27,215
+1,005% +$930K 1.17% 28
2018
Q1
$91K Sell
2,709
-313
-10% -$10.8K 0.08% 139
2017
Q4
$104K Buy
+3,022
New +$103K 0.09% 119

Other funds holding PFE

Blackhawk Capital Partners's PFE Position: Q1 2025 in Review

Blackhawk Capital Partners sold out of Pfizer (PFE) in Q1 2025, closing a stake of 17,267 shares — an estimated $458K sold.

Blackhawk Capital Partners first reported a position in PFE in Q4 2017 and held it in 14 quarters. The position peaked at $2.1M in Q2 2019. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Blackhawk Capital Partners reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Blackhawk Capital Partners sold 17,267 Pfizer shares in Q1 2025, an estimated $458K.
  • Blackhawk Capital Partners first reported a position in Pfizer in Q4 2017 and held it in 14 quarters.
  • Blackhawk Capital Partners's Pfizer position peaked at $2.1M in Q2 2019.
  • 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Blackhawk Capital Partners's 13F filing for Q1 2025, filed 30 Apr 2025.